Appendix Figure 2.
Resolution of anemia over the course of the study among participants with anemia at baseline who received canakinumab, 50, 150, or 300 mg every 3 months, compared with the placebo group.
HR = hazard ratio.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.